Handelsavisen
prelaunch
Companies Healthcare ALVIO.PA
AL
ALVIO.PA Euronext Paris Pharmaceuticals

Alvio.Pa

€0,74
Open in Charts → Attach watcher ⌖
EUR
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
-1 323,2 %
ROE
267,8 %
Net margin
-1 334,0 %
Debt / equity
-0,90
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

ALVIO.PA operates in the pharmaceuticals industry, focusing on drug development and research, and generates revenue primarily through the sale of pharmaceutical products and services.

Business. ALVIO.PA operates in the pharmaceuticals industry, focusing on drug development and research, and generates revenue primarily through the sale of pharmaceutical products and services.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
267,8 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning ALVIO.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to ALVIO.PA. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    ALVIO.PA operates in the pharmaceuticals industry, focusing on drug development and research, and generates revenue primarily through the sale of pharmaceutical products and services.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    ALVIO.PA exhibits a highly leveraged capital structure, with total liabilities of EUR 26.86 billion and total equity of EUR -8.93 billion, resulting in a negative debt-to-equity ratio of -0.9. The company's liquidity position is weak, with a current ratio of 0.25 and cash and equivalents of EUR 1.18 billion, which is insufficient to cover its EUR 8.03 billion in long-term debt. The negative free cash flow of EUR -23.56 billion and operating cash flow of EUR -8.37 billion further indicate significant liquidity constraints.

    Profitability metrics are severely negative, with a net loss of EUR -23.92 billion and an operating loss of EUR -23.73 billion. Return on equity is 2.68, but this is misleading due to the negative equity base. Return on assets is -1.33, indicating poor asset utilization. These figures fall well below the industry median for profitability and returns, suggesting underperformance relative to peers.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks and limits growth potential.

    Growth trajectory is negative, with a reported revenue of EUR 1.79 billion. Analyst estimates suggest a slight increase to EUR 1.8 billion, but this is not indicative of meaningful growth. The company's operating and net losses suggest a challenging path to profitability.

    Risk factors include high liquidity risk due to negative net cash and significant debt obligations. The company's dilution risk is currently low, but the negative equity position and high debt levels could necessitate future equity issuance, which would dilute existing shareholders. The risk assessment indicates a medium liquidity risk and a low dilution risk.

    Recent events include a reported net loss and negative operating cash flow, which are consistent with the company's financial challenges. No recent filings or transcripts have been disclosed that provide additional insight into the company's strategic direction or financial health.

    Key takeaways
    • ALVIO.PA is operating at a significant net loss with negative operating and free cash flows.
    • The company's capital structure is highly leveraged, with a negative equity position and high debt levels.
    • Profitability metrics are poor, with a negative return on assets and misleadingly high return on equity due to negative equity.
    • The company lacks geographic and segment diversification, increasing its exposure to market-specific risks.
    • Liquidity constraints are severe, with insufficient cash to cover long-term debt obligations.
    • The company's growth trajectory is negative, with minimal revenue growth and significant losses.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    €0,74
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    -€8.9M
    Net cash
    -€6.8M
    Current ratio
    0.2
    Debt / equity
    -0.9
    ROA
    -1.3%
    ROE
    2.7%
    Cash conversion
    35.0%
    CapEx / revenue
    -17.8%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-1 323,2 %Bottom quartile
    Net Margin-1 334,0 %Bottom quartile
    ROE267,8 %Best in class
    Capex / Rev-17,8 %Bottom quartile
    D/E-0,90Best in class
    Cash Conv0,35Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • ALVIO.PA Market data — financials · 2026-05-27
    • Valerio Therapeutics SA Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    ALVIO.PACanonical
    Euronext Paris · EUR

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage